Applied Nutrition is significantly expanding its product range to cater to customers using weight loss drugs, following a substantial increase in demand over the past year.
The health and wellness brand said it has identified a key business opportunity stemming from the sharp rise in Britons using GLP-1 treatments, such as Mounjaro and Wegovy.
The London-listed company, which already offers GLP-1-friendly high-protein ready meals launched in late 2025, confirmed that new products specifically designed for this market will be introduced later this year.
“The GLP-1 user is a growing customer. We see this as a consumer at the start of their weight loss journey who is now looking at how the medication can help them,” Thomas Ryder, founder and chief executive of the Liverpool-based firm, said.
“There is an opportunity, as those customers often need supplements and need smaller portions. I think this is a catalyst for the health and wellness space if we have that consumer in mind.
“We do have a number of products we will bring to market in this area because we do see that area growing."
At least 1.6 million Britons have used weight loss jabs in the past year, according to research by University College London.
Applied Nutrition has reported strong growth, driven by targeting new customer opportunities and diversifying its sales channels, including expansion into UK retail stores.
In March, the company announced robust financial results, with pre-tax profits soaring by 77.1% to £20.9 million for the six months ending 31 January, compared to the previous year.
Sales also saw a significant uplift, rising by 56.5 per cent to £74.5 million over the same half-year period.
However, the firm cautioned that sales volumes in the Middle East are expected to be affected by the ongoing conflict in the region.
Applied Nutrition said it still expects to meet revenue targets for the year of around £140 million.
The company added: “Importantly, we have managed similar disruption in the past, supported by the agility of our operations.
“In this instance, we are working closely with customers to adapt our routes into the region and logistics arrangements to safeguard continued supply to those customers.”
New research challenges what we know about yo-yo dieting
Expert reveals the seven biggest mistakes people on Mounjaro are making
What is orforglipron? The new weight-loss pill that could be a game-changer
Obesity pills are here – here’s why weight loss injections might be a thing of the past
Expert reveals the seven biggest mistakes people on Mounjaro are making
Boots offers discount on Mounjaro for patients who exercise
Stopping weight loss jabs could leave users ‘worse off than before’
